Valerio Nobili

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4583542/publications.pdf

Version: 2024-02-01

330 papers 17,505 citations

68 h-index 19136 118 g-index

331 all docs

331 docs citations

times ranked

331

17029 citing authors

#	Article	IF	CITATIONS
1	Nonalcoholic fatty liver disease. Nature Reviews Disease Primers, 2015, 1, 15080.	18.1	612
2	Gut microbiota profiling of pediatric nonalcoholic fatty liver disease and obese patients unveiled by an integrated metaâ€omicsâ€based approach. Hepatology, 2017, 65, 451-464.	3.6	572
3	Homozygosity for the patatin-like phospholipase-3/adiponutrin I148M polymorphism influences liver fibrosis in patients with nonalcoholic fatty liver disease. Hepatology, 2010, 51, 1209-1217.	3.6	563
4	The MBOAT7-TMC4 Variant rs641738 Increases Risk of Nonalcoholic Fatty Liver Disease in Individuals of European Descent. Gastroenterology, 2016, 150, 1219-1230.e6.	0.6	506
5	Transmembrane 6 superfamily member 2 gene variant disentangles nonalcoholic steatohepatitis from cardiovascular disease. Hepatology, 2015, 61, 506-514.	3.6	424
6	Diagnosis of Nonalcoholic Fatty Liver Disease in Children and Adolescents. Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 700-713.	0.9	405
7	Lifestyle intervention and antioxidant therapy in children with nonalcoholic fatty liver disease: A randomized, controlled trial. Hepatology, 2008, 48, 119-128.	3.6	362
8	Accuracy and reproducibility of transient elastography for the diagnosis of fibrosis in pediatric nonalcoholic steatohepatitis. Hepatology, 2008, 48, 442-448.	3.6	351
9	NAFLD in children: A prospective clinical-pathological study and effect of lifestyle advice. Hepatology, 2006, 44, 458-465.	3.6	324
10	Statin use and non-alcoholic steatohepatitis in at risk individuals. Journal of Hepatology, 2015, 63, 705-712.	1.8	309
11	I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease. Hepatology, 2010, 52, 1274-1280.	3.6	252
12	Performance of ELF Serum Markers in Predicting Fibrosis Stage in Pediatric Non-Alcoholic Fatty Liver Disease. Gastroenterology, 2009, 136, 160-167.	0.6	233
13	Ultrasonographic Quantitative Estimation of Hepatic Steatosis in Children With NAFLD. Journal of Pediatric Gastroenterology and Nutrition, 2011, 53, 190-195.	0.9	227
14	Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double-blind randomised controlled clinical trial. Archives of Disease in Childhood, 2011, 96, 350-353.	1.0	225
15	NAFLD in children: new genes, new diagnostic modalities and new drugs. Nature Reviews Gastroenterology and Hepatology, 2019, 16, 517-530.	8.2	199
16	Epigenetic mechanisms elicited by nutrition in early life. Nutrition Research Reviews, 2011, 24, 198-205.	2.1	192
17	The Kruppel-Like Factor 6 Genotype Is Associated With Fibrosis in Nonalcoholic Fatty Liver Disease. Gastroenterology, 2008, 135, 282-291.e1.	0.6	177
18	Medicinal plants and bioactive natural compounds in the treatment of non-alcoholic fatty liver disease: A clinical review. Pharmacological Research, 2018, 130, 213-240.	3.1	177

#	Article	IF	Citations
19	Mirnome analysis reveals novel molecular determinants in the pathogenesis of diet-induced nonalcoholic fatty liver disease. Laboratory Investigation, 2011, 91, 283-293.	1.7	176
20	Wilson's Disease in Children. Journal of Pediatric Gastroenterology and Nutrition, 2018, 66, 334-344.	0.9	171
21	Lipid-Induced Hepatocyte-Derived Extracellular Vesicles Regulate Hepatic Stellate Cells via MicroRNA Targeting Peroxisome Proliferator-Activated Receptor-γ. Cellular and Molecular Gastroenterology and Hepatology, 2015, 1, 646-663.e4.	2.3	170
22	Liver Biopsy in Children. Journal of Pediatric Gastroenterology and Nutrition, 2015, 60, 408-420.	0.9	165
23	Correlation of Serum TNF-α Levels and Histologic Liver Injury Scores in Pediatric Nonalcoholic Fatty Liver Disease. American Journal of Clinical Pathology, 2007, 127, 954-960.	0.4	162
24	The SOD2 C47T polymorphism influences NAFLD fibrosis severity: Evidence from case-control and intra-familial allele association studies. Journal of Hepatology, 2012, 56, 448-454.	1.8	156
25	A 360-degree overview of paediatric NAFLD: Recent insights. Journal of Hepatology, 2013, 58, 1218-1229.	1.8	154
26	Intestinal permeability is increased in children with non-alcoholic fatty liver disease, and correlates with liver disease severity. Digestive and Liver Disease, 2014, 46, 556-560.	0.4	142
27	Gut Microbiota Markers in Obese Adolescent and Adult Patients: Age-Dependent Differential Patterns. Frontiers in Microbiology, 2018, 9, 1210.	1.5	139
28	Pediatric non alcoholic fatty liver disease: old and new concepts on development, progression, metabolic insight and potential treatment targets. BMC Pediatrics, 2013, 13, 40.	0.7	138
29	Diagnosis, treatment and prevention of pediatric obesity: consensus position statement of the Italian Society for Pediatric Endocrinology and Diabetology and the Italian Society of Pediatrics. Italian Journal of Pediatrics, 2018, 44, 88.	1.0	136
30	The pediatric NAFLD fibrosis index: a predictor of liver fibrosis in children with non-alcoholic fatty liver disease. BMC Medicine, 2009, 7, 21.	2.3	132
31	Comparison of the Phenotype and Approach to Pediatric vs Adult Patients With Nonalcoholic Fatty Liver Disease. Gastroenterology, 2016, 150, 1798-1810.	0.6	129
32	The Role of Tissue Macrophage-Mediated Inflammation on NAFLD Pathogenesis and Its Clinical Implications. Mediators of Inflammation, 2017, 2017, 1-15.	1.4	129
33	Serum uric acid concentrations and fructose consumption are independently associated with NASH in children and adolescents. Journal of Hepatology, 2017, 66, 1031-1036.	1.8	128
34	Endotoxin and Plasminogen Activator Inhibitorâ€l Serum Levels Associated With Nonalcoholic Steatohepatitis in Children. Journal of Pediatric Gastroenterology and Nutrition, 2010, 50, 645-649.	0.9	126
35	Intrauterine Growth Retardation, Insulin Resistance, and Nonalcoholic Fatty Liver Disease in Children. Diabetes Care, 2007, 30, 2638-2640.	4.3	123
36	Hepatic progenitor cells activation, fibrosis, and adipokines production in pediatric nonalcoholic fatty liver disease. Hepatology, 2012, 56, 2142-2153.	3.6	123

#	Article	IF	CITATIONS
37	Docosahexaenoic acid for the treatment of fatty liver: Randomised controlled trial in children. Nutrition, Metabolism and Cardiovascular Diseases, 2013, 23, 1066-1070.	1.1	123
38	Low birth weight and catch-up-growth associated with metabolic syndrome: a ten year systematic review. Pediatric Endocrinology Reviews, 2008, 6, 241-7.	1.2	121
39	Metformin use in children with nonalcoholic fatty liver disease: An open-label, 24-month, observational pilot study. Clinical Therapeutics, 2008, 30, 1168-1176.	1.1	119
40	Pediatric nonalcoholic fatty liver disease, metabolic syndrome and cardiovascular risk. World Journal of Gastroenterology, 2011, 17, 3082-91.	1.4	119
41	Pediatric Nonalcoholic Fatty Liver Disease in 2009. Journal of Pediatrics, 2009, 155, 469-474.	0.9	117
42	Nonalcoholic Fatty Liver Disease. JAMA Pediatrics, 2015, 169, 170.	3.3	115
43	Nonalcoholic Fatty Liver Disease in Children. Seminars in Liver Disease, 2018, 38, 001-013.	1.8	108
44	Treatment of Wilson's disease with zinc from the time of diagnosis in pediatric patients: A single-hospital, 10-year follow-up study. Translational Research, 2005, 145, 139-143.	2.4	107
45	Serum Cytokeratin-18 Fragment Levels Are Useful Biomarkers for Nonalcoholic Steatohepatitis in Children. American Journal of Gastroenterology, 2013, 108, 1526-1531.	0.2	106
46	Role of Docosahexaenoic Acid Treatment in Improving Liver Histology in Pediatric Nonalcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e88005.	1.1	106
47	Obstructive Sleep Apnea Syndrome Affects Liver Histology and Inflammatory Cell Activation in Pediatric Nonalcoholic Fatty Liver Disease, Regardless of Obesity/Insulin Resistance. American Journal of Respiratory and Critical Care Medicine, 2014, 189, 66-76.	2.5	103
48	LPS-induced TNF- \hat{l}_{\pm} factor mediates pro-inflammatory and pro-fibrogenic pattern in non-alcoholic fatty liver disease. Oncotarget, 2015, 6, 41434-41452.	0.8	100
49	Pediatric nonalcoholic fatty liver disease: a multidisciplinary approach. Nature Reviews Gastroenterology and Hepatology, 2012, 9, 152-161.	8.2	99
50	The Benefit of Sleeve Gastrectomy in Obese Adolescents on Nonalcoholic Steatohepatitis and Hepatic Fibrosis. Journal of Pediatrics, 2017, 180, 31-37.e2.	0.9	95
51	Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: Pathogenetic role of genetic background and intrauterine environment. Annals of Medicine, 2012, 44, 29-40.	1.5	94
52	Indications and Limitations of Bariatric Intervention in Severely Obese Children and Adolescents With and Without Nonalcoholic Steatohepatitis. Journal of Pediatric Gastroenterology and Nutrition, 2015, 60, 550-561.	0.9	94
53	The rs2294918 E434K variant modulates patatinâ€like phospholipase domainâ€containing 3 expression and liver damage. Hepatology, 2016, 63, 787-798.	3.6	93
54	Vitamin D levels and liver histological alterations in children with nonalcoholic fatty liver disease. European Journal of Endocrinology, 2014, 170, 547-553.	1,9	92

#	Article	IF	Citations
55	Leptin, free leptin index, insulin resistance and liver fibrosis in children with non-alcoholic fatty liver disease. European Journal of Endocrinology, 2006, 155, 735-743.	1.9	91
56	A Combination of the Pediatric NAFLD Fibrosis Index and Enhanced Liver Fibrosis Test Identifies Children With Fibrosis. Clinical Gastroenterology and Hepatology, 2011, 9, 150-155.e1.	2.4	90
57	Association between Serum Atypical Fibroblast Growth Factors 21 and 19 and Pediatric Nonalcoholic Fatty Liver Disease. PLoS ONE, 2013, 8, e67160.	1.1	89
58	Combined paediatric <scp>NAFLD</scp> fibrosis index and transient elastography to predict clinically significant fibrosis in children with fatty liver disease. Liver International, 2013, 33, 79-85.	1.9	86
59	Plasma Levels of Homocysteine and Cysteine Increased in Pediatric NAFLD and Strongly Correlated with Severity of Liver Damage. International Journal of Molecular Sciences, 2014, 15, 21202-21214.	1.8	84
60	Docosahexanoic Acid Plus Vitamin D Treatment Improves Features of NAFLD in Children with Serum Vitamin D Deficiency: Results from a Single Centre Trial. PLoS ONE, 2016, 11, e0168216.	1.1	83
61	A protective effect of breastfeeding on the progression of non-alcoholic fatty liver disease. Archives of Disease in Childhood, 2009, 94, 801-805.	1.0	79
62	Oxidative stress parameters in paediatric non-alcoholic fatty liver disease. International Journal of Molecular Medicine, 2010, 26, 471-6.	1.8	78
63	Bifidobacteria and lactobacilli in the gut microbiome of children with non-alcoholic fatty liver disease: which strains act as health players?. Archives of Medical Science, 2018, 1, 81-87.	0.4	78
64	rs641738C>T near MBOAT7 is associated with liver fat, ALT and fibrosis in NAFLD: A meta-analysis. Journal of Hepatology, 2021, 74, 20-30.	1.8	77
65	Interferon lambda 4 rs368234815 TT>Î'G variant is associated with liver damage in patients with nonalcoholic fatty liver disease. Hepatology, 2017, 66, 1885-1893.	3.6	75
66	The APOC3 T-455C and C-482T promoter region polymorphisms are not associated with the severity of liver damage independently of PNPLA3 I148M genotype in patients with nonalcoholic fatty liver. Journal of Hepatology, 2011, 55, 1409-1414.	1.8	74
67	A 4â€Polymorphism Risk Score Predicts Steatohepatitis in Children With Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 632-636.	0.9	74
68	Retinol-Binding Protein 4: A Promising Circulating Marker of Liver Damage in Pediatric Nonalcoholic Fatty Liver Disease. Clinical Gastroenterology and Hepatology, 2009, 7, 575-579.	2.4	73
69	Development and validation of a new histological score for pediatric non-alcoholic fatty liver disease. Journal of Hepatology, 2012, 57, 1312-1318.	1.8	72
70	Gut-liver axis and fibrosis in nonalcoholic fatty liver disease: An input for novel therapies. Digestive and Liver Disease, 2013, 45, 543-551.	0.4	71
71	Epidemiology of fatty liver: an update. World Journal of Gastroenterology, 2014, 20, 9050-4.	1.4	71
72	Low levels of 25-hydroxyvitamin D3 in children with biopsy-proven nonalcoholic fatty liver disease. Hepatology, 2010, 51, 2229-2229.	3.6	69

#	Article	IF	CITATIONS
73	Good adherence to the Mediterranean diet reduces the risk for NASH and diabetes in pediatric patients with obesity: The results of an Italian Study. Nutrition, 2017, 39-40, 8-14.	1.1	69
74	Blind and ultrasound-guided percutaneous liver biopsy in children. Pediatric Radiology, 2003, 33, 772-775.	1.1	68
75	Glutathione metabolism and antioxidant enzymes in patients affected by nonalcoholic steatohepatitis. Clinica Chimica Acta, 2005, 355, 105-111.	0.5	68
76	Severity of Liver Injury and Atherogenic Lipid Profile in Children With Nonalcoholic Fatty Liver Disease. Pediatric Research, 2010, 67, 665-670.	1.1	68
77	The Development of the Pediatric NAFLD Fibrosis Score (PNFS) to Predict the Presence of Advanced Fibrosis in Children with Nonalcoholic Fatty Liver Disease. PLoS ONE, 2014, 9, e104558.	1.1	68
78	Nonalcoholic Fatty Liver Disease in Children. Journal of the American College of Nutrition, 2008, 27, 667-676.	1.1	67
79	Pediatric non-alcoholic fatty liver disease: Preventive andtherapeutic value of lifestyle intervention. World Journal of Gastroenterology, 2009, 15, 6017.	1.4	67
80	Hyaluronic acid predicts hepatic fibrosis in children with nonalcoholic fatty liver disease. Translational Research, 2010, 156, 229-234.	2.2	66
81	Nigella sativa (black seed) effects on plasma lipid concentrations in humans: A systematic review and meta-analysis of randomized placebo-controlled trials. Pharmacological Research, 2016, 106, 37-50.	3.1	66
82	Prevalence and Risk Factors of Significant Fibrosis in Patients With Nonalcoholic Fatty Liver Without Steatohepatitis. Clinical Gastroenterology and Hepatology, 2019, 17, 2310-2319.e6.	2.4	66
83	Portal inflammation is independently associated with fibrosis and metabolic syndrome in pediatric nonalcoholic fatty liver disease. Hepatology, 2016, 63, 745-753.	3.6	63
84	Intrauterine Growth Retardation and Nonalcoholic Fatty Liver Disease in Children. International Journal of Endocrinology, 2011, 2011, 1-8.	0.6	61
85	Dual Role of MicroRNAs in NAFLD. International Journal of Molecular Sciences, 2013, 14, 8437-8455.	1.8	61
86	The I148M Variant of PNPLA3 Reduces the Response to Docosahexaenoic Acid in Children with Non-Alcoholic Fatty Liver Disease. Journal of Medicinal Food, 2013, 16, 957-960.	0.8	60
87	Liver Stiffness in Pediatric Patients with Fatty Liver Disease: Diagnostic Accuracy and Reproducibility of Shear-Wave Elastography. Radiology, 2017, 283, 820-827.	3.6	60
88	Keratinocyte Growth Factor Receptor Ligands Target the Receptor to Different Intracellular Pathways. Traffic, 2007, 8, 1854-1872.	1.3	59
89	<i>LPIN1</i> rs13412852 Polymorphism in Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2012, 54, 588-593.	0.9	59
90	Intima-media thickness and liver histology in obese children and adolescents with non-alcoholic fatty liver disease. Atherosclerosis, 2010, 209, 463-468.	0.4	57

#	Article	IF	CITATIONS
91	Influence of dietary pattern, physical activity, and I148M PNPLA3 on steatosis severity in at-risk adolescents. Genes and Nutrition, 2014, 9, 392.	1.2	56
92	A "systems medicine―approach to the study of non-alcoholic fatty liver disease. Digestive and Liver Disease, 2016, 48, 333-342.	0.4	56
93	Risk of severe liver disease in NAFLD with normal ALT levels: A pediatric report. Hepatology, 2008, 48, 2087-2088.	3.6	54
94	Efficacy of docosahexaenoic acid–choline–vitamin E in paediatric NASH: a randomized controlled clinical trial. Applied Physiology, Nutrition and Metabolism, 2017, 42, 948-954.	0.9	53
95	Focal adhesion kinase depletion reduces human hepatocellular carcinoma growth by repressing enhancer of zeste homolog 2. Cell Death and Differentiation, 2017, 24, 889-902.	5.0	53
96	Markers of activated inflammatory cells correlate with severity of liver damage in children with nonalcoholic fatty liver disease. International Journal of Molecular Medicine, 2012, 30, 49-56.	1.8	52
97	The role of lifestyle changes in the management of chronic liver disease. BMC Medicine, 2011, 9, 70.	2.3	51
98	Serum Bilirubin Level Is Inversely Associated With Nonalcoholic Steatohepatitis in Children. Journal of Pediatric Gastroenterology and Nutrition, 2013, 57, 114-118.	0.9	51
99	MicroRNAs as controlled systems and controllers in non-alcoholic fatty liver disease. World Journal of Gastroenterology, 2014, 20, 15079.	1.4	51
100	Nutritional and lipidomics biomarkers of docosahexaenoic acid-based multivitamin therapy in pediatric NASH. Scientific Reports, 2019, 9, 2045.	1.6	51
101	Macrophage Activation in Pediatric Nonalcoholic Fatty Liver Disease (NAFLD) Correlates with Hepatic Progenitor Cell Response via Wnt3a Pathway. PLoS ONE, 2016, 11, e0157246.	1.1	50
102	Bloodletting Ameliorates Insulin Sensitivity and Secretion in Parallel to Reducing Liver Iron in Carriers of <i>HFE</i> Gene Mutations. Diabetes Care, 2008, 31, 3-8.	4.3	49
103	Emodin Prevents Intrahepatic Fat Accumulation, Inflammation and Redox Status Imbalance During Diet-Induced Hepatosteatosis in Rats. International Journal of Molecular Sciences, 2012, 13, 2276-2289.	1.8	48
104	\hat{l}^2 -Klotho gene variation is associated with liver damage in children with NAFLD. Journal of Hepatology, 2020, 72, 411-419.	1.8	48
105	Non invasive evaluation of liver fibrosis in paediatric patients with nonalcoholic steatohepatitis. World Journal of Gastroenterology, 2006, 12, 7821.	1.4	48
106	Elevated serum ALT in children presenting to the emergency unit: Relationship with NAFLD. Digestive and Liver Disease, 2009, 41, 749-752.	0.4	47
107	Pathogen- or damage-associated molecular patterns during nonalcoholic fatty liver disease development. Hepatology, 2011, 54, 1500-1502.	3.6	47
108	Altered gut–liver axis and hepatic adiponectin expression in OSAS: novel mediators of liver injury in paediatric non-alcoholic fatty liver. Thorax, 2015, 70, 769-781.	2.7	47

#	Article	IF	CITATIONS
109	Preemptive liver transplantation in a child with familial hypercholesterolemia. Pediatric Transplantation, 2011, 15, E25-9.	0.5	45
110	ADAR Enzyme and miRNA Story: A Nucleotide that Can Make the Difference. International Journal of Molecular Sciences, 2013, 14, 22796-22816.	1.8	45
111	Levels of Serum Ceruloplasmin Associate With Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2013, 56, 370-375.	0.9	45
112	Nonalcoholic fatty liver disease and atherosclerosis. Internal and Emergency Medicine, 2012, 7, 297-305.	1.0	44
113	Cannabinoid Receptor Type 2 Functional Variant Influences Liver Damage in Children with Non-Alcoholic Fatty Liver Disease. PLoS ONE, 2012, 7, e42259.	1.1	44
114	Causative role of gut microbiota in non-alcoholic fatty liver disease pathogenesis. Frontiers in Cellular and Infection Microbiology, 2012, 2, 132.	1.8	44
115	EZH2 Down-Regulation Exacerbates Lipid Accumulation and Inflammation in in Vitro and in Vivo NAFLD. International Journal of Molecular Sciences, 2013, 14, 24154-24168.	1.8	44
116	Relationship Between PNPLA3 rs738409 Polymorphism and Decreased Kidney Function in Children With NAFLD. Hepatology, 2019, 70, 142-153.	3.6	44
117	Nonâ€alcoholic fatty liver disease and hepatocellular carcinoma in a 7â€yearâ€old obese boy: coincidence or comorbidity?. Pediatric Obesity, 2014, 9, e99-e102.	1.4	42
118	Plasma Cytokeratinâ€18 Level As a Novel Biomarker for Liver Fibrosis in Children With Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, 181-187.	0.9	42
119	PCSK7 gene variation bridges atherogenic dyslipidemia with hepatic inflammation in NAFLD patients. Journal of Lipid Research, 2019, 60, 1144-1153.	2.0	42
120	Serum Bile Acid Levels in Children With Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2015, 61, 85-90.	0.9	41
121	OSAS-Related Inflammatory Mechanisms of Liver Injury in Nonalcoholic Fatty Liver Disease. Mediators of Inflammation, 2015, 2015, 1-10.	1.4	41
122	Plasma Cathepsin D Levels: A Novel Tool to Predict Pediatric Hepatic Inflammation. American Journal of Gastroenterology, 2015, 110, 462-470.	0.2	40
123	Prevalence of prediabetes and diabetes in children and adolescents with biopsy-proven non-alcoholic fatty liver disease. Journal of Hepatology, 2019, 71, 802-810.	1.8	39
124	Association between type two diabetes and non-alcoholic fatty liver disease in youth. Annals of Hepatology, 2009, 8, S44-S50.	0.6	38
125	Atherogenic Dyslipidemia and Cardiovascular Risk Factors in Obese Children. International Journal of Endocrinology, 2015, 2015, 1-9.	0.6	38
126	Low Birthweight Increases the Likelihood of Severe Steatosis in Pediatric Non-Alcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2017, 112, 1277-1286.	0.2	38

#	Article	IF	CITATIONS
127	Nonalcoholic Fatty Liver in Children and Adolescents: An Overview. Journal of Adolescent Health, 2012, 51, 305-312.	1.2	37
128	Unraveling the genetics of fatty liver in obese children: Additive effect of P446L GCKR and I148M PNPLA3 polymorphisms. Hepatology, 2012, 55, 661-663.	3.6	37
129	Omega-3 fatty acids: Mechanisms of benefit and therapeutic effects in pediatric and adult NAFLD. Critical Reviews in Clinical Laboratory Sciences, 2016, 53, 106-120.	2.7	37
130	Clinical implications of understanding the association between oxidative stress and pediatric NAFLD. Expert Review of Gastroenterology and Hepatology, 2017, 11, 371-382.	1.4	37
131	Hepatic farnesoid X receptor protein level and circulating fibroblast growth factor 19 concentration in children with <scp>NAFLD</scp> . Liver International, 2018, 38, 342-349.	1.9	37
132	Early interplay of intra-hepatic iron and insulin resistance in children with non-alcoholic fatty liver disease. Journal of Hepatology, 2011, 55, 647-653.	1.8	36
133	Drug Transporters and Multiple Drug Resistance in the Most Common Pediatric Solid Tumors. Current Drug Metabolism, 2016, 17, 308-316.	0.7	35
134	Nonalcoholic Fatty Liver Disease in Children. Pediatric Clinics of North America, 2017, 64, 659-675.	0.9	35
135	The Health Care Transition of Youth With Liver Disease Into the Adult Health System. Journal of Pediatric Gastroenterology and Nutrition, 2018, 66, 976-990.	0.9	35
136	Nonalcoholic fatty liver disease in children. Current Opinion in Clinical Nutrition and Metabolic Care, 2010, 13, 397-402.	1.3	34
137	Transient elastography for assessment of fibrosis in paediatric liver disease. Pediatric Radiology, 2011, 41, 1232-1238.	1.1	34
138	Non-Alcoholic Fatty Liver and Metabolic Syndrome in Children: A Vicious Circle. Hormone Research in Paediatrics, 2014, 82, 283-289.	0.8	34
139	Does vitamin E improve the outcomes of pediatric nonalcoholic fatty liver disease? A systematic review and meta-analysis. Saudi Journal of Gastroenterology, 2014, 20, 143.	0.5	34
140	Is juvenile liver biopsy unsafe? Putting an end to a common misapprehension. Pediatric Radiology, 2009, 39, 959-961.	1.1	33
141	Extrahepatic portal vein thrombosis in children and adolescents: Influence of genetic thrombophilic disorders. World Journal of Gastroenterology, 2010, 16, 6123.	1.4	33
142	Biochemical Parameters and Anthropometry Predict NAFLD in Obese Children. Journal of Pediatric Gastroenterology and Nutrition, 2011, 53, 590-593.	0.9	33
143	Insulin-Like Growth Factor-I and -II Levels Are Associated with the Progression of Nonalcoholic Fatty Liver Disease in Obese Children. Journal of Pediatrics, 2014, 165, 92-98.	0.9	33
144	Evaluations of Lifestyle, Dietary, and Pharmacologic Treatments for Pediatric Nonalcoholic Fatty Liver Disease: A Systematic Review. Clinical Gastroenterology and Hepatology, 2019, 17, 1457-1476.e7.	2.4	33

#	Article	IF	Citations
145	Non-alcoholic fatty liver disease in children now: Lifestyle changes and pharmacologic treatments. Nutrition, 2012, 28, 722-726.	1.1	32
146	Management of chronic hepatitis <scp>B</scp> in children: An unresolved issue. Journal of Gastroenterology and Hepatology (Australia), 2014, 29, 912-919.	1.4	32
147	I148M PNPLA3 variant and progressive liver disease: A new paradigm in hepatology. Hepatology, 2012, 56, 791-791.	3.6	30
148	<scp>O</scp> balon intragastric balloon in the treatment of paediatric obesity: a pilot study. Pediatric Obesity, 2015, 10, e1-4.	1.4	30
149	Association Between Nonalcoholic Fatty Liver Disease and Reduced Bone Mineral Density in Children: A Metaâ€Analysis. Hepatology, 2019, 70, 812-823.	3.6	30
150	Tyrosinemia Type 1: Metastatic Hepatoblastoma With a Favorable Outcome. Pediatrics, 2010, 126, e235-e238.	1.0	29
151	A review of the pathogenic and therapeutic role of nutrition in pediatric nonalcoholic fatty liver disease. Nutrition Research, 2018, 58, 1-16.	1.3	29
152	Toll-like receptor-mediated signaling cascade as a regulator of the inflammation network during alcoholic liver disease. World Journal of Gastroenterology, 2014, 20, 16443.	1.4	29
153	Liver Fibrosis and Therapeutic Strategies: The Goal for Improving Metabolism. Current Drug Targets, 2009, 10, 505-512.	1.0	28
154	Pediatric postâ€transplant metabolic syndrome: New clouds on the horizon. Pediatric Transplantation, 2013, 17, 216-223.	0.5	28
155	Hepatitis E in Children. Journal of Pediatric Gastroenterology and Nutrition, 2016, 63, 288-294.	0.9	28
156	Laparoscopic Sleeve Gastrectomy Improves Nonalcoholic Fatty Liver Disease–Related Liver Damage in Adolescents by Reshaping Cellular Interactions and Hepatic Adipocytokine Production. Journal of Pediatrics, 2018, 194, 100-108.e3.	0.9	28
157	Albuminuria and insulin resistance in children with biopsy proven non-alcoholic fatty liver disease. Pediatric Nephrology, 2009, 24, 1211-1217.	0.9	27
158	Autoimmune hepatitis type 2 following anti-papillomavirus vaccination in a 11-year-old girl. Vaccine, 2011, 29, 4654-4656.	1.7	27
159	Protein glutathionylation increases in the liver of patients with nonâ€alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2008, 23, e457-64.	1.4	26
160	Use of metformin in pediatric age. Pediatric Diabetes, 2011, 12, no-no.	1.2	26
161	Liver fibrosis in paediatric liver diseases. Bailliere's Best Practice and Research in Clinical Gastroenterology, 2011, 25, 259-268.	1.0	26
162	Autoimmune hepatitis in children. European Journal of Gastroenterology and Hepatology, 2012, 24, 739-746.	0.8	26

#	Article	IF	CITATIONS
163	Meta-Omic Platforms to Assist in the Understanding of NAFLD Gut Microbiota Alterations: Tools and Applications. International Journal of Molecular Sciences, 2014, 15, 684-711.	1.8	26
164	Nonalcoholic Fatty Liver Disease in Italian Children with Down Syndrome: Prevalence and Correlation with Obesity-Related Features. Journal of Pediatrics, 2017, 189, 92-97.e1.	0.9	26
165	Celiac Disease in Pediatric Patients with Autoimmune Hepatitis. Paediatric Drugs, 2012, 14, 35-41.	1.3	25
166	Recent advances in understanding the role of adipocytokines during non-alcoholic fatty liver disease pathogenesis and their link with hepatokines. Expert Review of Gastroenterology and Hepatology, 2016, 10, 393-403.	1.4	25
167	Circulating Soluble Fas and Fas Ligand Levels Are Elevated in Children with Nonalcoholic Steatohepatitis. Digestive Diseases and Sciences, 2015, 60, 2353-2359.	1.1	24
168	Reduced lysosomal acid lipase activity – A potential role in the pathogenesis of non alcoholic fatty liver disease in pediatric patients. Digestive and Liver Disease, 2016, 48, 909-913.	0.4	24
169	Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2018, 66, 188-192.	0.9	24
170	Plasma Nâ€terminal propeptide of type III procollagen accurately predicts liver fibrosis severity in children with nonâ€alcoholic fatty liver disease. Liver International, 2019, 39, 2317-2329.	1.9	24
171	The Antioxidant Effects of Hydroxytyrosol and Vitamin E on Pediatric Nonalcoholic Fatty Liver Disease, in a Clinical Trial: A New Treatment?. Antioxidants and Redox Signaling, 2019, 31, 127-133.	2.5	24
172	Fatty liver and insulin resistance in children with hypobetalipoproteinemia: the importance of aetiology. Clinical Endocrinology, 2013, 79, 49-54.	1.2	23
173	Non-high-density lipoprotein cholesterol (non-HDL-C) levels in children with nonalcoholic fatty liver disease (NAFLD). SpringerPlus, 2014, 3, 407.	1.2	23
174	Combined Test for UGT1A1 –3279T→G and A(TA)nTAA Polymorphisms Best Predicts Gilbert's Syndrome in Italian Pediatric Patients. Genetic Testing and Molecular Biomarkers, 2006, 10, 121-125.	1.7	22
175	Plasma high mobility group box 1 protein reflects fibrosis in pediatric nonalcoholic fatty liver disease. Expert Review of Molecular Diagnostics, 2014, 14, 763-771.	1.5	22
176	Macrophages and fibrosis in adipose tissue are linked to liver damage and metabolic risk in obese children. Obesity, 2014, 22, 1512-1519.	1.5	22
177	A non-invasive prediction model for non-alcoholic steatohepatitis in paediatric patients with non-alcoholic fatty liver disease. Digestive and Liver Disease, 2014, 46, 1008-1013.	0.4	22
178	Beverage consumption and paediatric NAFLD. Eating and Weight Disorders, 2016, 21, 581-588.	1.2	22
179	The Liver in Children With Metabolic Syndrome. Frontiers in Endocrinology, 2019, 10, 514.	1.5	22
180	The Role of Genetic Predisposition, Programing During Fetal Life, Family Conditions, and Post-natal Diet in the Development of Pediatric Fatty Liver Disease. Journal of Pediatrics, 2019, 211, 72-77.e4.	0.9	22

#	Article	IF	Citations
181	Childhood NAFLD: a ticking time-bomb?. Gut, 2009, 58, 1442-1442.	6.1	21
182	Is Non-Alcoholic Fatty Liver Disease Less Frequent among Women with Prader-Willi Syndrome?. Obesity Facts, 2014, 7, 71-76.	1.6	21
183	Pediatric liver diseases: current challenges and future perspectives. Expert Review of Gastroenterology and Hepatology, 2016, 10, 255-265.	1.4	21
184	A new ABCB11 mutation in two Italian children with familial intrahepatic cholestasis. Journal of Gastroenterology, 2006, 41, 598-603.	2.3	20
185	An 8-year-old boy with autoimmune hepatitis and Candida onychosis as the first symptoms of autoimmune polyglandular syndrome (APS1): identification of a new homozygous mutation in the autoimmune regulator gene (aire). European Journal of Pediatrics, 2008, 167, 949-953.	1.3	20
186	Long-term challenges and perspectives of pre-adolescent liver disease. The Lancet Gastroenterology and Hepatology, 2017, 2, 435-445.	3.7	20
187	Liver zonation in children with nonâ€alcoholic fatty liver disease: Associations with dietary fructose and uric acid concentrations. Liver International, 2018, 38, 1102-1109.	1.9	20
188	Does Nox2 Overactivate in Children with Nonalcoholic Fatty Liver Disease?. Antioxidants and Redox Signaling, 2019, 30, 1325-1330.	2.5	20
189	Comparison between non-alcoholic fatty liver disease screening guidelines in children and adolescents. JHEP Reports, 2019, 1, 259-264.	2.6	20
190	Autoimmune Thyroiditis Associated with Autoimmune Hepatitis. Thyroid, 2005, 15, 1193-1195.	2.4	19
191	Paediatric non-alcoholic fatty liver disease. Gut, 2010, 59, 561-564.	6.1	19
192	Paediatric Non-Alcoholic Fatty Liver Disease: Impact on Patients and Mothers' Quality of Life. Hepatitis Monthly, 2013, 13, e7871.	0.1	19
193	Epidemiology and Natural History of Nafld/Epidemiologija I Prirodna Istorija Nealkoholne Masne Jetre. Journal of Medical Biochemistry, 2014, 34, 13-17.	0.7	19
194	The pharmacological management of NAFLD in children and adolescents. Expert Review of Clinical Pharmacology, 2017, 10, 1225-1237.	1.3	19
195	Arterial Stiffness, Thickness and Association to Suitable Novel Markers of Risk at the Origin of Cardiovascular Disease in Obese Children. International Journal of Medical Sciences, 2017, 14, 711-720.	1.1	19
196	Association between type two diabetes and non-alcoholic fatty liver disease in youth. Annals of Hepatology, 2009, 8 Suppl 1, S44-50.	0.6	19
197	Diagnostic power of fibroscan in predicting liver fibrosis in nonalcoholic fatty liver disease. Hepatology, 2009, 50, 2048-2049.	3.6	18
198	Glutathionylation of p65NF-κB correlates with proliferating/apoptotic hepatoma cells exposed to proand anti-oxidants. International Journal of Molecular Medicine, 2009, 24, 319-26.	1.8	18

#	Article	IF	Citations
199	Paediatric nonalcoholic fatty liver disease. Current Opinion in Gastroenterology, 2013, 29, 279-284.	1.0	18
200	The association between retinal microvascular changes, metabolic risk factors, and liver histology in pediatric patients with non-alcoholic fatty liver disease (NAFLD). Journal of Gastroenterology, 2015, 50, 903-912.	2.3	18
201	Fructose at the center of necroinflammation and fibrosis in nonalcoholic steatohepatitis1. Hepatology, 2011, 53, 372-373.	3.6	17
202	Insulin resistance and exercise capacity in male children and adolescents with non-alcholic fatty liver disease. Acta Diabetologica, 2009, 46, 97-104.	1.2	16
203	Thyroid Function Tests in Obese Prepubertal Children: Correlations with Insulin Sensitivity and Body Fat Distribution. Hormone Research in Paediatrics, 2012, 78, 100-105.	0.8	16
204	Portal hypertension in children. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 260-261.	0.7	16
205	Pediatric non-alcoholic fatty liver disease: Recent advances. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 419-422.	0.7	16
206	European paediatric non-alcoholic fatty liver disease registry (EU-PNAFLD): Design and rationale. Contemporary Clinical Trials, 2018, 75, 67-71.	0.8	16
207	The Number of Liver Galectin-3 Positive Cells Is Dually Correlated with NAFLD Severity in Children. International Journal of Molecular Sciences, 2019, 20, 3460.	1.8	16
208	Autoimmune hemolytic anemia and autoimmune hepatitis associated with parvovirus B19 infection. Pediatric Infectious Disease Journal, 2004, 23, 184-185.	1.1	15
209	Unmet needs in pediatric NAFLD research: what do we need to prioritize for the future?. Expert Review of Gastroenterology and Hepatology, 2018, 12, 961-967.	1.4	15
210	Redox homeostasis and posttranslational modifications/activity of phosphatase and tensin homolog in hepatocytes from rats with diet-induced hepatosteatosis. Journal of Nutritional Biochemistry, 2012, 23, 169-178.	1.9	14
211	PNPLA3 rs738409 Polymorphism Predicts Development and Severity of Hepatic Steatosis but Not Metabolic Syndrome in Celiac Disease. Nutrients, 2018, 10, 1239.	1.7	14
212	The Contribution of the Adipose Tissue-Liver Axis in Pediatric Patients with Nonalcoholic Fatty Liver Disease after Laparoscopic Sleeve Gastrectomy. Journal of Pediatrics, 2020, 216, 117-127.e2.	0.9	14
213	Aminotransferases as predictors of mortality. Lancet, The, 2008, 371, 1822-1823.	6.3	13
214	Expert opinion on current therapies for nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy, 2011, 12, 1901-1911.	0.9	13
215	A practical approach to the child with abnormal liver tests. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 259-262.	0.7	13
216	The IRGM rs10065172 variant increases the risk for steatosis but not for liver damage progression in Italian obese children. Journal of Hepatology, 2017, 67, 653-655.	1.8	13

#	Article	IF	CITATIONS
217	Relationship between portal chronic inflammation and disease severity in paediatric non-alcoholic fatty liver disease. Digestive and Liver Disease, 2011, 43, 143-146.	0.4	12
218	Fatty liver disease and obesity in youth. Current Opinion in Endocrinology, Diabetes and Obesity, 2016, 23, 66-71.	1.2	12
219	Fighting Fatty Liver Diseases with Nutritional Interventions, Probiotics, Symbiotics, and Fecal Microbiota Transplantation (FMT). Advances in Experimental Medicine and Biology, 2018, 1125, 85-100.	0.8	12
220	Relationship between nonâ€alcoholic steatohepatitis, PNPLA3 I148M genotype and bone mineral density in adolescents. Liver International, 2018, 38, 2301-2308.	1.9	12
221	Programming, metabolic syndrome, and NAFLD: The challenge of transforming a vicious cycle into a virtuous cycle. Journal of Hepatology, 2010, 52, 788-790.	1.8	11
222	Viral Hepatitis in Children. Journal of Pediatric Gastroenterology and Nutrition, 2012, 55, 500-505.	0.9	11
223	Early Glucose Derangement Detected by Continuous Glucose Monitoring and Progression of Liver Fibrosis in Nonalcoholic Fatty Liver Disease: An Independent Predictive Factor?. Hormone Research in Paediatrics, 2016, 85, 29-34.	0.8	11
224	Co-occurrence of chronic hepatitis B virus infection and autoimmune hepatitis in a young Senegalese girl. European Journal of Gastroenterology and Hepatology, 2006, 18, 927-929.	0.8	10
225	Biomarkers in Nonalcoholic Fatty Liver Disease: A New Era in Diagnosis and Staging of Disease in Children. Journal of Pediatric Gastroenterology and Nutrition, 2010, 51, 378-379.	0.9	10
226	Toll-like receptor 4: A starting point for proinflammatory signals in fatty liver disease. Hepatology, 2010, 51, 714-715.	3.6	10
227	Targeted therapy in children—what is the right way?. Nature Reviews Gastroenterology and Hepatology, 2011, 8, 425-426.	8.2	10
228	Alcoholic and Non-alcoholic Fatty Liver in Adolescents: A Worrisome Convergence. Alcohol and Alcoholism, 2011, 46, 627-629.	0.9	10
229	Association between nocturnal blood pressure dipping and insulin resistance in children affected by NAFLD. European Journal of Pediatrics, 2014, 173, 1511-1518.	1.3	10
230	Macrophage Markers Are Poorly Associated With Liver Histology in Children With Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2018, 67, 635-642.	0.9	10
231	In a pilot study, reduced fatty acid desaturase 1 function was associated with nonalcoholic fatty liver disease and response to treatment in children. Pediatric Research, 2018, 84, 696-703.	1.1	10
232	Are children after liver transplant more prone to nonâ€alcoholic fatty liver disease?. Pediatric Transplantation, 2008, 12, 611-613.	0.5	9
233	Treatment of nonalcoholic fatty liver disease in adults and children: a closer look at the arsenal. Journal of Gastroenterology, 2012, 47, 29-36.	2.3	9
234	Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease. Expert Opinion on Pharmacotherapy, 2014, 15, 2501-2511.	0.9	9

#	Article	IF	Citations
235	AISF update on the diagnosis and management of adult-onset lysosomal storage diseases with hepatic involvement. Digestive and Liver Disease, 2020, 52, 359-367.	0.4	9
236	Molecular genetics of NASH: The role of polymorphisms. Journal of Hepatology, 2007, 47, 868-869.	1.8	8
237	Letters to the Editor. Journal of Paediatrics and Child Health, 2007, 43, 414-414.	0.4	8
238	How much we worry for liver fat in children?. Acta Paediatrica, International Journal of Paediatrics, 2007, 96, 1373-1373.	0.7	8
239	Treatment of chronic hepatitis C in children: Is it necessary and, if so, in whom?. Journal of Hepatology, 2010, 52, 472-474.	1.8	8
240	Vitamin D and liver fibrosis: let's start soon before it's too late. Gut, 2015, 64, 698-699.	6.1	8
241	Therapeutic strategies for pediatric non-alcoholic fatty liver disease: A challenge for health care providers. World Journal of Gastroenterology, 2007, 13, 2639.	1.4	8
242	Novel large-range mitochondrial DNA deletions and fatal multisystemic disorder with prominent hepatopathy. Biochemical and Biophysical Research Communications, 2011, 415, 300-304.	1.0	7
243	Successful Tenofovir Treatment for Fulminant Hepatitis B Infection in an Infant. Pediatric Infectious Disease Journal, 2011, 30, 912-914.	1.1	7
244	The use of ultrasound in clinical setting for children affected by NAFLD: is it safe and accurate?. Italian Journal of Pediatrics, 2011, 37, 36.	1.0	7
245	Commentary: FGF21 Holds Promises for Treating Obesity-related Insulin Resistance and Hepatosteatosis. Endocrinology, 2014, 155, 343-346.	1.4	7
246	Docosahexaenoic Acid and Its Role in G-Protein-Coupled Receptor 120 Activation in Children Affected by Nonalcoholic Fatty Liver Disease. Endocrine Development, 2016, 30, 29-36.	1.3	7
247	High concentrations of H2O2 trigger hypertrophic cascade and phosphatase and tensin homologue (PTEN) glutathionylation in H9c2 cardiomyocytes. Experimental and Molecular Pathology, 2016, 100, 199-206.	0.9	7
248	The relationship between body mass index and children's presentations to a tertiary pediatric emergency department. Italian Journal of Pediatrics, 2018, 44, 38.	1.0	7
249	Food allergy in pediatric liver transplant recipients: Harmful or harmless?. Pediatric Transplantation, 2007, 11, 1-2.	0.5	6
250	Children Unresponsive to Hepatitis B Virus Vaccination Also Need Celiac Disease Testing. Journal of Pediatric Gastroenterology and Nutrition, 2012, 55, e131.	0.9	6
251	Hedgehog/hyaluronic acid interaction network in nonalcoholic fatty liver disease, fibrosis, and hepatocellular carcinoma. Hepatology, 2012, 56, 1589-1589.	3.6	6
252	Non-alcoholic fatty liver disease in children and adolescents. Clinical Biochemistry, 2014, 47, 720.	0.8	6

#	Article	IF	CITATIONS
253	Low Serum Potassium Levels Associated with Disease Severity in Children with Nonalcoholic Fatty Liver Disease. Pediatric Gastroenterology, Hepatology and Nutrition, 2015, 18, 168.	0.4	6
254	Arginase 1: A potential marker of a common pattern of liver steatosis in HCV and NAFLD children. Journal of Hepatology, 2015, 62, 1207-1208.	1.8	6
255	Expression of insulin-like growth factor I and its receptor in the liver of children with biopsy-proven NAFLD. PLoS ONE, 2018, 13, e0201566.	1.1	6
256	Association of Bright Liver with the PNPLA3 I148M Gene Variant in 1-year-old Toddlers. Journal of Clinical Endocrinology and Metabolism, 2019, 104, 2163-2170.	1.8	6
257	Is torquetenovirus a potential cause of liver damage in children?. Journal of Infection, 2005, 50, 368-369.	1.7	5
258	Steatosis and fibrosis in paediatric liver transplant: Insidious graft's enemies - A call for clinical studies and research. Pediatric Transplantation, 2010, 14, 441-444.	0.5	5
259	Activation of the endotoxin/toll-like receptor 4 pathway: The way to go from nonalcoholic steatohepatitis up to hepatocellular carcinoma. Hepatology, 2011, 53, 1069-1069.	3.6	5
260	Is there any link between dietary pattern and development of nonalcoholic fatty liver disease in adolescence? An expert review. Expert Review of Gastroenterology and Hepatology, 2013, 7, 601-604.	1.4	5
261	Meaurement of advanced glycation end products may change NASH managment. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 1354-1355.	1.4	4
262	Intensive Treatment and Dietary Fats in Adolescents With Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2008, 46, 224-224.	0.9	4
263	Profiling microRNA expression: A snapshot of nonalcoholic steatohepatitis and a recording of its pathogenesis. Hepatology, 2009, 49, 706-707.	3.6	4
264	Acute liver failure and pediatric ALF: strategic help for the pediatric hepatologist. Journal of Pediatrics, 2010, 156, 342.	0.9	4
265	Human hepatic stellate cells are liver-resident antigen-presenting cells. Hepatology, 2011, 54, 1107-1107.	3.6	4
266	Hepatitis B virus infection in children. Clinics and Research in Hepatology and Gastroenterology, 2012, 36, 291-293.	0.7	4
267	Metabolic disorders: all that we know from circulating biomarkers. Biomarkers in Medicine, 2012, 6, 707-709.	0.6	4
268	Omega-3 Fatty Acids and Fatty Liver Disease in Children. Advances in Food and Nutrition Research, 2018, 85, 59-77.	1.5	4
269	Clinical course of infection with hepatitis C. BMJ: British Medical Journal, 2006, 332, 374-375.	2.4	3
270	Utility of magnetic resonance imaging in the evaluation of hepatic fat content. Hepatology, 2009, 50, 328-329.	3.6	3

#	Article	IF	Citations
271	Portal inflammation as index of steatohepatitis in children with nonalcoholic fatty liver disease. Hepatology, 2009, 50, 659-659.	3.6	3
272	PNPLA3 I148M polymorphism and liver damage in obese children. Journal of Pediatrics, 2011, 159, 876.	0.9	3
273	Transient elastography and serum biomarkers: two-step screening methods for liver fibrosis in non-alcoholic fatty liver disease before liver biopsy. Expert Opinion on Medical Diagnostics, 2012, 6, 377-380.	1.6	3
274	Non-alcoholic fatty liver disease. Paediatrics and Child Health (United Kingdom), 2013, 23, 529-534.	0.2	3
275	Deciphering the Role of ω3 Fatty Acids in Nonalcoholic Steatohepatitis. Journal of Pediatric Gastroenterology and Nutrition, 2014, 59, 423-424.	0.9	3
276	Nutritional considerations in children with chronic liver disease. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1805-1806.	1.4	2
277	Acute liver failure as presenting feature of tyrosinemia type 1 in a child with primary HHV-6 infection. Journal of Gastroenterology and Hepatology (Australia), 2006, 21, 339-339.	1.4	2
278	Fulminant Hepatic Failure Following Measles. Pediatric Infectious Disease Journal, 2007, 26, 766-767.	1.1	2
279	Molecular Pathogenesis of Nonalcoholic Steatohepatitis. American Journal of Pathology, 2007, 171, 712-713.	1.9	2
280	Bioinformatics as tool to identify gene/protein-pathways associated with nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology, 2007, 46, 1306-1306.	3.6	2
281	Hepatitis C Virus and Nonalcoholic Fatty Liver Disease: Similar Risk Factors for Necroinflammation, Fibrosis, and Cirrhosis. Clinical Gastroenterology and Hepatology, 2010, 8, 97.	2.4	2
282	Dual role of survivin in nonâ€alcoholic fatty liver disease. Liver International, 2011, 31, 1416-1417.	1.9	2
283	The wide spectrum of hepatic iron overload. Hepatology, 2011, 53, 1057-1058.	3.6	2
284	Hepatic stellate cell proliferation: A potential role of protein kinase R. Hepatology, 2011, 54, 1484-1485.	3.6	2
285	Metabolic Syndrome and Alcohol Abuse: A Potential Hepatocarcinogenic Mix in Adolescents. Clinical Gastroenterology and Hepatology, 2012, 10, 204.	2.4	2
286	Fatty liver in adolescents: Mechanisms, clinical features and therapy. Journal of Hepatology, 2016, 65, 1258-1260.	1.8	2
287	The Use of Probiotics in Pediatric Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2017, 64, 336-337.	0.9	2
288	Preventing liver fibrosis in patients with NAFLD and the road ahead. Expert Review of Gastroenterology and Hepatology, 2017, 11, 1081-1083.	1.4	2

#	Article	IF	CITATIONS
289	First case of nonalcoholic steatohepatitis in a child with del(1p36) and dup (Xp22): review of the literature. Clinical Dysmorphology, 2018, 27, 42-45.	0.1	2
290	NGM282: a step forward in the nonalcoholic steatohepatitis treatment landscape?. Hepatobiliary Surgery and Nutrition, 2018, 7, 484-486.	0.7	2
291	The Evaluation of Hepatic Fibrosis Scores in Children with Nonalcoholic Fatty Liver Disease. American Journal of Gastroenterology, 2013, 108, S624.	0.2	2
292	CHILDHOOD HEPATITIS C VIRUS INFECTION Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1948-1949.	1.4	1
293	Autoimmune sclerosing cholangitis in two sisters. European Journal of Pediatrics, 2007, 167, 107-108.	1.3	1
294	Reduced cardio-respiratory fitness in obesity with and without nonalcoholic fatty liver disease. Hepatology, 2008, 48, 690-690.	3.6	1
295	Natural approach against lipotoxic traffic in nonalcoholic fatty liver disease. Hepatology, 2010, 52, 399-399.	3.6	1
296	The link between hepatosteatosis and cells of the immune system. Hepatology, 2010, 51, 1472-1472.	3.6	1
297	Recent advances in biomarkers for noninvasive diagnosis of nonalcoholic steatohepatitis: the role of lipid analysis/profiling. Clinical Lipidology, 2011, 6, 427-436.	0.4	1
298	Supplementation of Monounsaturated and Polyunsaturated Fatty Acids in Nonâ€Alcoholic Fatty Liver Disease and Metabolic Syndrome. Lipids, 2011, 46, 389-90.	0.7	1
299	Metabolic syndrome and nonalcoholic steatohepatitis recurrence after liver transplantation in children. Liver Transplantation, 2011, 17, 620-621.	1.3	1
300	Circulating biomarkers for metabolic disorders as a predictor of cardiovascular disease risk: what's new?. Biomarkers in Medicine, 2012, 6, 715-718.	0.6	1
301	Non-Alcoholic Fatty Liver Disease in Children. Pediatric and Adolescent Medicine, 2012, , 104-115.	0.4	1
302	Daclatasvir: a promising triple therapy for children with chronic hepatitis C. Lancet Infectious Diseases, The, 2013, 13, 17-18.	4.6	1
303	Retinoids counteract insulin resistance and liver steatosis: What's the potential mechanism?. Hepatology, 2013, 58, 1185-1185.	3.6	1
304	NASH and the Cross-Talk Between the Gut and Liver. Current Pediatrics Reports, 2014, 2, 211-217.	1.7	1
305	Targeting FGF19 binding to its receptor system: A novel therapeutic approach for hepatocellular carcinoma. Hepatology, 2015, 62, 1324-1324.	3.6	1
306	Obesity and Nonalcoholic Fatty Liver Disease in Children. , 2019, , 209-222.		1

#	Article	lF	CITATIONS
307	Fatty Liver Disease. , 2010, , 201-222.		1
308	Indirect markers of fibrosis in chronic liver diseases: Is aspartate transaminase-to-platelet ratio (APRI) a useful test?. Hepatitis Monthly, 2011, 11, 558-9.	0.1	1
309	HCV and steatosis in children. Journal of Hepatology, 2006, 45, 758.	1.8	O
310	Different fat distribution as marker of disease in nonalcholic fatty liver disease. Hepatology, 2007, 46, 1310-1311.	3.6	0
311	Lifestyle advice in non-alcoholic fatty liver disease. Journal of Gastroenterology and Hepatology (Australia), 2007, 22, 604-605.	1.4	0
312	Reply to T.U. Hoogenraad's paper published last April. Brain and Development, 2007, 29, 55.	0.6	0
313	Clinical observation paper: Fatty liver and metabolic syndrome: is it a burden for the future generations?. Metabolism: Clinical and Experimental, 2010, 59, 831-833.	1.5	0
314	Effect of treatment with polyunsaturated fatty acids on HCV- or diet-induced fatty liver. Journal of Hepatology, 2011, 54, 1325-1326.	1.8	0
315	Role of Fatty Liver Disease in Childhood Obesity. , 2011, , 221-230.		0
316	T regulatory cell number and function: The autoimmune traits in liver diseases. Journal of Hepatology, 2012, 57, 1398-1399.	1.8	0
317	La steatosi epatica in età pediatrica: Ã" parte intégrante della sindrome metabolica?. L Endocrinologo, 2013, 14, 25-30.	0.0	0
318	Metabolic syndrome: new therapeutic approaches. Italian Journal of Pediatrics, 2014, 40, .	1.0	0
319	Genetic Insight Into the Pathogenesis of Nonalcoholic Fatty Liver Disease. Journal of Pediatric Gastroenterology and Nutrition, 2014, 58, 139-140.	0.9	0
320	Insulin-like growth factors (IGF-I and -II): new actors in the development of non-alcoholic fatty liver disease. Expert Review of Endocrinology and Metabolism, 2014, 9, 193-195.	1.2	0
321	The author's reply: Pancreatic fat and hepatoâ€metabolic features in obese children with nonalcoholic fatty liver disease. Clinical Endocrinology, 2016, 84, 307-307.	1.2	0
322	Author response re. "Mediterranean diet to prevent/treat nonalcoholic fatty liver disease in children: A promising approach― Nutrition, 2017, 43-44, 99-100.	1.1	0
323	Fatty Liver Disease. Contemporary Endocrinology, 2018, , 451-462.	0.3	0
324	Reply to "Definition of Small for Gestational Age and Low Birthweight― American Journal of Gastroenterology, 2018, 113, 442.	0.2	0

#	Article	IF	CITATIONS
325	Reply to: "Energy drinks and adolescents – A hepatic health hazard?― Journal of Hepatology, 2018, 68, 857-858.	1.8	0
326	Nonalcoholic Fatty Liver Disease and Steatohepatitis in Children. , 2019, , 279-291.		0
327	Postâ€transplant metabolic syndrome in children: Know better to cure better. Pediatric Transplantation, 2019, 23, e13367.	0.5	O
328	Wilson Disease in a Child With Mild Neuropsychiatric and Hepatic Involvement. Journal of Pediatric Gastroenterology and Nutrition, 2019, 69, e118-e119.	0.9	0
329	Human herpesvirus type 6 hepatitis or familiar intrahepatic cholestasis: the importance of follow-up. BMJ Case Reports, 2009, 2009, bcr0820080623-bcr0820080623.	0.2	0
330	NAFLD in Children: Implication for the Future. , 2020, , 211-223.		0